Yu Chang

3.6k total citations · 1 hit paper
96 papers, 2.7k citations indexed

About

Yu Chang is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Yu Chang has authored 96 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pathology and Forensic Medicine, 36 papers in Oncology and 29 papers in Molecular Biology. Recurrent topics in Yu Chang's work include Lymphoma Diagnosis and Treatment (38 papers), Viral-associated cancers and disorders (14 papers) and Immune Cell Function and Interaction (11 papers). Yu Chang is often cited by papers focused on Lymphoma Diagnosis and Treatment (38 papers), Viral-associated cancers and disorders (14 papers) and Immune Cell Function and Interaction (11 papers). Yu Chang collaborates with scholars based in China, United States and Australia. Yu Chang's co-authors include Ping’an Ma, Jun Lin, Ziyong Cheng, Xinyang Zhang, Haihua Xiao, Haiqin Song, Jinqiang Wang, Zhen Gu, Jianhua Liu and Chunxia Li and has published in prestigious journals such as Advanced Materials, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Yu Chang

92 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enhanced Cisplatin Chemotherapy by Iron Oxide Nanocarrier-Mediated Generation of Highly Toxic Reactive Oxygen Species

2017 603 citations Yu Chang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yu Chang China	26	845	838	684	611	570	96	2.7k
David M. Weinreich United States	20	685 0.8×	427 0.5×	453 0.7×	207 0.3×	360 0.6×	32	2.8k
Jiandong Wang China	29	1.3k 1.6×	519 0.6×	553 0.8×	180 0.3×	471 0.8×	139	3.3k
Hao Fu China	31	1.0k 1.2×	794 0.9×	738 1.1×	100 0.2×	476 0.8×	164	3.3k
Behzad Baradaran Iran	28	1.4k 1.6×	773 0.9×	757 1.1×	146 0.2×	209 0.4×	113	2.9k
Shuzhong Cui China	25	1.4k 1.7×	699 0.8×	668 1.0×	114 0.2×	352 0.6×	91	2.9k
Mohammad Hedayati United States	30	1.7k 2.0×	426 0.5×	529 0.8×	246 0.4×	187 0.3×	61	2.8k
Jean‐Louis Merlin France	30	974 1.2×	586 0.7×	963 1.4×	289 0.5×	274 0.5×	154	2.7k
Qichun Wei China	30	1.2k 1.4×	523 0.6×	903 1.3×	106 0.2×	205 0.4×	138	3.2k
Anthony M. Davies Ireland	25	871 1.0×	572 0.7×	381 0.6×	189 0.3×	586 1.0×	51	2.3k

Countries citing papers authored by Yu Chang

Since Specialization

Citations

This map shows the geographic impact of Yu Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Chang more than expected).

Fields of papers citing papers by Yu Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Chang. The network helps show where Yu Chang may publish in the future.

Co-authorship network of co-authors of Yu Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Chang. A scholar is included among the top collaborators of Yu Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Chang. Yu Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chang, Yu, et al.. (2025). Association between Healthy Eating Index-2020, alternative Mediterranean Diet scores, and gastrointestinal cancer risk in NHANES 2005–2018. Scientific Reports. 15(1). 3983–3983. 3 indexed citations

Jing, Xiang, Fankun Meng, Yu Chang, et al.. (2025). The application of avatrombopag in chronic liver disease patients with severe thrombocytopenia undergoing procedures in China: a prospective real-world cohort study. International Journal of Surgery. 111(12). 9228–9238.

Chang, Yu, et al.. (2024). Engineering Stimuli‐Responsive Materials for Precision Medicine. Small. 21(1). e2406439–e2406439. 27 indexed citations

Li, Wenqi, Yu Chang, Xi-Yang Liu, et al.. (2024). Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study. Annals of Hematology. 103(6). 2003–2012.

Chen, Pengfei, Mengfan Zhang, Tengfei Li, et al.. (2024). Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial. Signal Transduction and Targeted Therapy. 9(1). 304–304. 4 indexed citations

Chang, Yu, et al.. (2023). Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose-induced oncogenic effect by downregulating the Warburg effect. Medical Oncology. 40(10). 297–297. 6 indexed citations

Chang, Yu, et al.. (2022). The Effect of Chronic Rhinosinusitis on the Staging and Prognosis of Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Retrospective Analysis. Frontiers in Oncology. 12. 878559–878559.

Yu, Hui, Xiaorui Fu, Lei Zhang, et al.. (2021). Clinical analysis of patients with primary and secondary extranodal natural killer/T‐cell lymphoma of central nervous system. Hematological Oncology. 41(2). 267–274. 2 indexed citations

Li, Ling, Lei Zhang, Xin Li, et al.. (2021). Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. Indian Journal of Hematology and Blood Transfusion. 38(1). 42–50. 2 indexed citations

10.

Zhang, Lei, Yan Wang, Xin Li, et al.. (2020). Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T‐cell lymphoma: A randomized, controlled, open‐label, multicenter study. International Journal of Cancer. 148(6). 1470–1477. 10 indexed citations

11.

Chang, Yu, Xiaojiang Wu, Li L, et al.. (2019). Clinical features and prognostic factors of primary bone marrow lymphoma. SHILAP Revista de lepidopterología. 2 indexed citations

12.

Ma, Qianwen, Yu Chang, Ling Li, et al.. (2019). Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. Cancer Management and Research. Volume 11. 1363–1372. 7 indexed citations

13.

Chang, Yu, Xiyang Liu, Wencai Li, et al.. (2019). Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III–IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus. Cancer Management and Research. Volume 11. 3555–3564. 14 indexed citations

14.

Li, Ling, Ken H. Young, Lei Zhang, et al.. (2017). Efficacy and Safety of Novel Targeted Drug' Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study. Blood. 130. 1548–1548. 2 indexed citations

15.

Li, Ling, Wenjing Duan, Lei Zhang, et al.. (2017). The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T‐cell lymphoma with analysis of biomarkers. British Journal of Haematology. 178(5). 772–780. 21 indexed citations

16.

Zhang, Lin, Yu Chang, Min Xu, et al.. (2017). Salidroside attenuates hypoxia-induced pulmonary arterial smooth muscle cell proliferation and apoptosis resistance by upregulating autophagy through the AMPK-mTOR-ULK1 pathway. BMC Pulmonary Medicine. 17(1). 191–191. 81 indexed citations

17.

Cui, Yingying, Xin Li, Zhenchang Sun, et al.. (2015). Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. Leukemia & lymphoma. 56(9). 2613–2618. 11 indexed citations

18.

Sun, Zhenchang, Xin Li, Xiaolong Wu, et al.. (2014). Clinical analysis of chronic lung injury in patients with non-Hodgkin lymphoma after CHOP chemotherapy. Tumor Biology. 35(12). 12601–12605.

19.

Chang, Yu. (2009). Analysis of HBV Infection in Non-Hodgkin Lymphoma. 1 indexed citations

20.

Chang, Yu, et al.. (1999). A Novel Percutaneous Barrier Device that Permits Safe Subcutaneous Access. ASAIO Journal. 45(6). 531–534. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact